Efficacy and safety of first-line immune checkpoint inhibitors combinations for extensive-stage small-cell lung cancer: A systematic review and network meta-ana
Combining immune checkpoint inhibitors (ICIs) with chemotherapy has become a major clinical research focus. Patients with extensive-stage small-cell lung cancer (ES-SCLC) have been treated with different first-line ICI combinations in randomized controlled trials (RCTs), but the
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.